Not sure many takers, report is pretty pricey.
I did note this in the excerpt:
“Key Hyperhidrosis Therapies expected to launch in the market are BOTOX, BBI-4000 (Sofpironium bromide), THVD-102, Umeclidinium, AT-5214, and many others.
In May 2023, Botanix Pharmaceuticals announced that a study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.”
Is this information accurate, it mentions BOT still conducting studies on safety and efficacy of 3 concentrations?
It also mentions a number of other treatments? My only concern about SB has been the degree of competition. Any others have thoughts on this?
BOT - Anything but charting, page-4938
-
- There are more pages in this discussion • 4,334 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.015(3.95%) |
Mkt cap ! $660.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $2.097M | 5.772M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 209038 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 123594 | 9 |
View Market Depth
| Last trade - 11.04am 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |